hero image

A Statement from Biogen on Access to LEQEMBI™

March 13, 2023 Corporate

Biogen welcomes the U.S. Veterans Health Administration’s (VHA) recent decision to provide coverage of LEQEMBITM for veterans living with early stages of Alzheimer’s disease. Additional details can be found in Eisai’s news release announcing the coverage decision.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

thumb
February 13, 2024
Biogen Reports Fourth Quarter and Full Year 2023 Results
thumb
February 12, 2024
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients